Abstract:Tenofovir is a nucleotidic analog inhibitor used in monotherapy as first line treatment of chronic Hepatitis B virus (HBV) infection. This drug requires a two-step phosphorylation by cellular kinases. The active triphosphate form inhibits viral DNA polymerase. Tenofovir has a very low oral bioavailability following oral administration. Hence, its oral administration requires the use of prodrugs: tenofovir disoproxil fumararate (TDF) or tenofovir alafénamide (TAF). TAF demonstrated a lower kidney and bone toxicity than TDF. TAF and TDF treatments allow prevention of chronic hepatitis B complications, which are cirrhosis and hepatocellular carcinoma. Prevention of these complications requires a virological response to the treatment, defined as undetectable HBV DNA. TDF and TAF are associated with virological response rates from 64 to 94 % after one year of treatment. This rate depends on HBV viral load at diagnostic, HBe antigen status, mutations in the HBV polymerase gene (Pol/RT) and patient compliance to the treatment. Tenofovir has a high genetic barrier and resistance mutations to this drug have not yet been described. However, mutations rt181T/V and/or rtN236T have been associated with reduced susceptibility to TDF/TAF in vitro and delayed response in vivo. Recently described mutations CYEI and rtA194T have been associated with reduced susceptibility to TDF/TAF in vitro without any change in viral response in vivo. Patient compliance can be improved using cognitive behavioral therapy, supporter interventions and use of short message service. Finally, some genetic polymorphisms in MRP(multidrug resistance-associated protein)-2 and MRP4 efflux transporters could be associated with TDF toxicity and virological response to TDF or TAF. In the perspective of functional HBV cure, TDF and TAF are likely to be still used, in association with new class of antivirals. For this reason, it is important to further characterize the pharmacological and virological factors associated with partial virological response to tenofovir.

Progress on antiviral tenofovir

Advances on Tenofovir for the Treatment of Other Nucleoside Analogue Resistant Chronic Hepatitis B

Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study.

Research Progress of HIV-1 Integrase and Its Inhibitors

Clinical efficacy and safety of ravidavir-based antiretroviral regimen in treatment of patients with chronic hepatitis C

[Treatment of chronic hepatitis B: virological and pharmacological aspects]

Effects of Tenofovir Combined with Recombinant Human Interferon Α-2B on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Progress in the Antiviral Treatment of HBV-related Cirrhosis

Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?

An O-Benzyl Phosphonamidate Prodrug of Tenofovir for the Treatment of Hepatitis B Virus Infection

Recent Progresses on Pentacyclic Triterpene-Based Antiviral Agents

Current trends and advances in antiviral therapy for chronic hepatitis B

From Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Perspectives in Pediatric Patients with Chronic Hepatitis B

Discovery and development of antiviral drugs

Progress in Nucleoside and Nucleotide Analogue Therapy for Chronic Hepatitis B

Tenofovir rescue therapy in pregnant females with chronic hepatitis B.

Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues.

Recent advance of the hepatitis B virus inhibitors: a medicinal chemistry overview

Recent Advance in Antiviral Drugs for Hepatitis C.

Clinical Applications of Antiviral Agents